salbutamol + ensifentrine

This is a **combination of salbutamol (a short-acting beta2-adrenoceptor agonist bronchodilator)** and **ensifentrine (previously known as RPL554, a "bifunctional" inhaled dual phosphodiesterase 3/4 inhibitor with both bronchodilator and anti-inflammatory action)**. The combination is investigated for **chronic obstructive pulmonary disease (COPD)**, aiming to provide enhanced bronchodilation and reduction of lung hyperinflation compared to monotherapy. Ensifentrine's bronchodilator action is mediated by PDE3 inhibition in airway smooth muscle, while anti-inflammatory effects are via PDE4 inhibition in inflammatory cells. Salbutamol stimulates beta2-adrenoceptors causing muscle relaxation and bronchodilation. Clinical studies show this combination leads to significantly greater improvements in lung function (FEV1) and reduced lung trapping than either agent alone, with an acceptable safety profile[1][3][5].

Brand names

Ohtuvayre

Other names

salbutamol + RPL554salbutamol + VMX554salbutamol + ensifentrinesalbutamol + VRP554